ABUS vs. OCS, CMPS, ANAB, KALV, APLT, STOK, FULC, ANL, AVBP, and ATXS
Should you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Oculis (OCS), COMPASS Pathways (CMPS), AnaptysBio (ANAB), KalVista Pharmaceuticals (KALV), Applied Therapeutics (APLT), Stoke Therapeutics (STOK), Fulcrum Therapeutics (FULC), Adlai Nortye (ANL), ArriVent BioPharma (AVBP), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical preparations" industry.
Oculis (NASDAQ:OCS) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, community ranking, valuation, earnings, analyst recommendations, institutional ownership and profitability.
In the previous week, Oculis had 12 more articles in the media than Arbutus Biopharma. MarketBeat recorded 15 mentions for Oculis and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.52 beat Oculis' score of -0.33 indicating that Oculis is being referred to more favorably in the media.
Arbutus Biopharma received 407 more outperform votes than Oculis when rated by MarketBeat users. However, 85.00% of users gave Oculis an outperform vote while only 70.78% of users gave Arbutus Biopharma an outperform vote.
Arbutus Biopharma has higher revenue and earnings than Oculis.
22.3% of Oculis shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 4.0% of Arbutus Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Oculis has a net margin of 0.00% compared to Oculis' net margin of -401.57%. Arbutus Biopharma's return on equity of 0.00% beat Oculis' return on equity.
Oculis currently has a consensus target price of $29.14, suggesting a potential upside of 125.04%. Arbutus Biopharma has a consensus target price of $4.33, suggesting a potential upside of 58.73%. Given Arbutus Biopharma's higher possible upside, equities research analysts plainly believe Oculis is more favorable than Arbutus Biopharma.
Summary
Oculis beats Arbutus Biopharma on 9 of the 14 factors compared between the two stocks.
Get Arbutus Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arbutus Biopharma Competitors List
Related Companies and Tools
